Chapter 9. Current Challenges in the Adjuvant Therapy of Colon Cancer

  1. John H. Scholefield1,
  2. Axel Grothey2,
  3. Herand Abcarian3 and
  4. Tim Maughan4
  1. George P. Kim and
  2. Axel Grothey

Published Online: 14 JAN 2008

DOI: 10.1002/9780470753231.ch9

Challenges in Colorectal Cancer

Challenges in Colorectal Cancer

How to Cite

Kim, G. P. and Grothey, A. (2006) Current Challenges in the Adjuvant Therapy of Colon Cancer, in Challenges in Colorectal Cancer (eds J. H. Scholefield, A. Grothey, H. Abcarian and T. Maughan), Blackwell Publishing Ltd, Malden, Massachusetts, USA. doi: 10.1002/9780470753231.ch9

Editor Information

  1. 1

    Professor of Surgery, University Hospital, Nottingham, UK

  2. 2

    Professor, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA

  3. 3

    Turi Josefsen Professor and Chairman, Department of Surgery, University of Illinois College of Medicine, Chicago, Illinois, USA

  4. 4

    Professor of Cancer Studies, University of Cardiff, Cardiff, UK

Publication History

  1. Published Online: 14 JAN 2008
  2. Published Print: 1 JAN 2006

ISBN Information

Print ISBN: 9781405127066

Online ISBN: 9780470753231

SEARCH

Keywords:

  • adjuvant therapy;
  • colon cancer;
  • patient population;
  • mortality;
  • chemotherapy

Summary

This chapter contains section titled:

  • Introduction

  • How is 5-FU best administered in the adjuvant setting?

  • What survival outcome should be the primary endpoint for adjuvant colorectal trials?

  • What is the role of oxaliplatin in the adjuvant setting?

  • Should irinotecan be used in adjuvant treatment?

  • What is the role of capecitabine in stage III colon cancer adjuvant treatment?

  • Should stage II colon cancer patients receive treatment?

  • Does microsatellite instability predict which patients will benefit from adjuvant treatment?

  • Should the biologic agents cetuximab or bevacizumab be added to treatment regimens?

  • Conclusions